
Abbott Labs (ABT) Stock Forecast & Price Target
Abbott Labs (ABT) Analyst Ratings
Bulls say
Abbott Laboratories is poised for strong financial performance, with an expected organic sales growth of 6.0-7.0% for 2025, supported by a robust 13.7% organic growth in its Electrophysiology business driven by recent product launches. The company also reported significant growth across its Diabetes (16.2%), Rhythm Management (13.0%), and Structural Heart (11.3%) segments, reflecting strong demand and market share gains in key therapeutic areas. Additionally, Abbott’s commitment to consistent dividend increases, maintained for over 50 consecutive years, underscores its solid financial health and potential for future value creation.
Bears say
Abbott Laboratories faces significant challenges impacting its financial outlook, particularly due to a sharp decline in Covid-19 testing-related sales, which fell to $69 million in Q3 2025 from $265 million in the previous year, indicating a persistent headwind. Additionally, macroeconomic pressures such as inflation and foreign exchange fluctuations are likely to exacerbate these challenges, contributing to lower-than-expected revenue across various segments, including Rapid Diagnostics. The impact of these factors, including underperformance in key product areas like CoreLab in China, has led to a mixed set of results, raising concerns about the company's ability to sustain organic revenue growth and profitability in the near term.
This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.
Abbott Labs (ABT) Analyst Forecast & Price Prediction
Start investing in Abbott Labs (ABT)
Order type
Buy in
Order amount
Est. shares
0 shares